Skip to content

betamethasone valerate on post-cryotherapy

The effects of topical betamethasone valerate on post-cryotherapy inflammation in cutaneous wart treatment

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170818035762N3
Enrollment
40
Registered
2020-05-30
Start date
2019-04-04
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin wart. Viral warts

Interventions

Intervention 1: Intervention group: In our study, patients with skin warts in two different organs were included. The first intervention group was given one of the organs with betamethasone valrate af

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with skin wart who are diagnosed by a dermatologist clinically or pathologically and have cryotherapy indications. Patients over 2 years of age They have a conscious consent to enter the study the maximum number of warts is up to 20

Exclusion criteria

Exclusion criteria: pregnant and lactating women People treated with systemic medications that interfere with wound healing or immuno suppressive drugs Patients who have contraindications for cryotherapy Patients who have used topical medications other than emollients in the past month People who are allergic to betamethasone or topical steroids Patients with wound healing disorders such as diabetes Distributed and resistant warts that need further treatment

Design outcomes

Primary

MeasureTime frame
Tolerance of pain to cryotherapy treatment. Timepoint: Day 1,7 and 14. Method of measurement: Vas scale.

Secondary

MeasureTime frame
Illness severity. Timepoint: At the beginning of the study. Method of measurement: Based on the number of warts.;Duration of illness. Timepoint: At the beginning of the study. Method of measurement: Number of days before starting treatment.;Eritrea. Timepoint: The second, eighth and fifteenth day after starting treatment. Method of measurement: Based on the examination.;Blisters. Timepoint: The second, eighth and fifteenth day after starting treatment. Method of measurement: Based on the examination.;Scar. Timepoint: The second, eighth and fifteenth day after starting treatment. Method of measurement: Based on the examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArmaghan Kazeminezhad

Mazandaran University of Medical Sciences

a.kazeminejad@mazums.ac.ir+98 11 4221 8021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026